Clinical trials in Woluwe-Saint-Lambert – page 4

In Woluwe-Saint-Lambert, a large share of clinical research focuses on cancer and related blood disorders, with studies spanning solid tumors and hematologic malignancies. The main goal is to test new treatment options, improve disease control, and extend survival for patients with advanced or hard-to-treat disease.

• Breast cancer, lung cancer, colorectal cancer, and prostate cancer
• Leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes
• Melanoma, ovarian cancer, bladder cancer, and head and neck cancers
• Evaluating targeted therapies, immunotherapy, and improved treatment combinations

Research at the city’s sites also includes biomarker-driven studies, aiming to match therapies more closely to tumor characteristics and resistance patterns.

Another major area covers digestive system diseases and liver disorders, including chronic inflammatory conditions and metabolic liver disease. These trials are designed to reduce symptoms, control inflammation, and assess whether newer therapies can improve long-term outcomes.

• Crohn’s disease, ulcerative colitis, and inflammatory bowel disease
• Primary biliary cholangitis, primary sclerosing cholangitis, and cholestatic pruritus
• Non-alcoholic steatohepatitis, metabolic dysfunction-associated steatotic liver disease, and cirrhosis
• Testing better symptom relief, disease control, and safety of emerging treatments

Several studies also explore conditions such as pancreatic, gastric, and biliary cancers linked to the gastrointestinal tract.

Clinical trials in immune system diseases and autoimmune disorders are prominent, reflecting broad interest in chronic inflammatory illnesses. The research aims to improve symptom management, reduce flares, and support longer-term disease control.

• Rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis
• Lupus, myasthenia gravis, and multiple sclerosis
• Atopic dermatitis, psoriasis, urticaria, and vitiligo
• Studying targeted immune-modulating therapies and treatment durability

This area also includes rare immune-mediated conditions, giving patients access to research beyond standard care.

A substantial part of the research portfolio centers on respiratory tract diseases and chronic lung conditions. These trials seek better ways to ease breathing problems, slow disease progression, and improve quality of life.

• Asthma, chronic obstructive pulmonary disease, and bronchiectasis
• Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
• Chronic rhinosinusitis, pneumonia, and refractory chronic cough
• Evaluating new anti-inflammatory and disease-modifying approaches

Some studies also address severe respiratory infections and complex lung disease, highlighting the breadth of pulmonary research in the city.

Trials in cardiovascular diseases and metabolic disorders are aimed at lowering risk, protecting organ function, and preventing complications. The focus includes both common chronic illnesses and high-risk conditions with major long-term health impact.

• Heart failure, coronary artery disease, and atherosclerotic cardiovascular disease
• Hypertension, elevated lipoprotein(a), and symptomatic hypertrophic cardiomyopathy
• Obesity, type 1 diabetes, and metabolic liver disease
• Testing therapies that may improve cardiovascular outcomes and metabolic control

Research in this field often combines prevention-focused studies with treatment studies for patients already living with advanced disease.

Research on kidney diseases and urologic disorders forms another important part of the clinical landscape. Studies are examining ways to preserve kidney function, reduce proteinuria, and manage hereditary or progressive renal conditions.

• Chronic kidney disease, proteinuric kidney disease, and kidney failure
• Autosomal dominant polycystic kidney disease and Alport syndrome
• Urothelial carcinoma, bladder cancer, and prostate cancer
• Evaluating renal protection, symptom control, and new cancer therapies

The work includes both adult and pediatric studies, reflecting interest in kidney health across the lifespan.

Nervous system diseases are well represented, with trials addressing both chronic neurologic disorders and conditions that affect cognition and movement. The overall aim is to slow progression, improve function, and support daily independence.

• Multiple sclerosis, epilepsy, and narcolepsy
• Alzheimer’s disease, mild cognitive impairment, and early cognitive decline
• Myasthenia gravis, cerebral palsy, and rare neurodevelopmental disorders
• Testing therapies that may modify disease activity or improve symptoms

This area includes both common neurological conditions and rare diseases, adding depth to the city’s research profile.

Clinical trials in skin and connective tissue diseases are exploring chronic inflammatory and autoimmune skin conditions, as well as hair and pigmentation disorders. The goal is to improve symptom relief, skin appearance, and long-term disease control.

• Atopic dermatitis, psoriasis, and hidradenitis suppurativa
• Vitiligo, alopecia areata, and prurigo nodularis
• Lupus-related skin disease and chronic cutaneous lupus erythematosus
• Assessing newer targeted treatments for persistent dermatologic disease

These studies often focus on conditions that can strongly affect comfort, self-image, and quality of life.

A notable portion of the research portfolio addresses congenital, hereditary, and neonatal diseases, with an emphasis on children and rare disorders. These trials aim to fill treatment gaps where options are limited or still evolving.

• Congenital adrenal hyperplasia, growth disorders, and prematurity-related conditions
• Rare genetic kidney, liver, and metabolic diseases
• Neurodevelopmental disorders such as Rett syndrome and CDKL5 deficiency disorder
• Evaluating therapies for rare, inherited, or early-onset diseases

The presence of pediatric and orphan-disease research adds an important specialist dimension to the city’s clinical trial activity.

Trials in bacterial infections and mycoses, virus diseases, and broader public health topics address both treatment and prevention. Research is focused on limiting complications, improving recovery, and strengthening care for vulnerable patients.

• HIV infection, hepatitis B, cytomegalovirus, and varicella
• Pneumonia, sepsis, candidemia, and invasive fungal infections
• Monkeypox and other emerging infectious threats
• Testing prevention strategies and better infection management approaches

Some studies also support transplant and immunocompromised patients, where infection risk is especially high.

The city also hosts trials in hemic and lymphatic diseases, including bleeding disorders and other blood-related conditions. These studies are designed to improve safety, reduce complications, and offer more effective long-term management.

• Hemophilia A, hemophilia B, and paroxysmal nocturnal hemoglobinuria
• Anemia associated with chronic kidney disease and coagulopathy
• Thrombotic microangiopathy and hemolytic uremic syndrome
• Evaluating replacement, supportive, and disease-modifying therapies

This research area often overlaps with kidney disease, transplantation, and rare inherited disorders.

A smaller but important set of studies addresses mental disorders, behavior, and sleep-related problems. These trials look for ways to improve daily functioning, mood, and overall well-being.

• Major depressive disorder, cognitive symptoms, and anhedonia
• Narcolepsy and sleep disturbances linked to hormonal changes
• Behavioral and psychological aspects of chronic illness
• Exploring supportive treatments that may improve quality of life

This adds breadth to the trial landscape by addressing symptoms that affect both physical and emotional health.